Business
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif., March 20, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full-year ended December 31, 2024, and highlighted recent progress across its pipeline of clinical-stage product candidates.
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/047dcd9e505b5f339f6958d029756a45"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g4lMDsFw5f1KXYpYlr.2Ng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/047dcd9e505b5f339f6958d029756a45","width":960,"height":311},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ZFJIOsuPHkwUAK2Ch58MOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/047dcd9e505b5f339f6958d029756a45","width":1200,"height":388}},"lazy":false},{"type":"text","content":"– Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 –","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"– Completed enrollment in ALTO-203 Phase 2 proof-of-concept MDD trial; on track to report topline data in the second quarter of 2025 –","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"– Novel transdermal formulation of ALTO-101 demonstrated greater drug exposure and improved tolerability profile; topline data from Phase 2 trial of ALTO-101 in schizophrenia expected in the second half of 2025 –","length":212,"tagName":"p","attribs":{}},{"type":"text","content":"– Company’s precision psychiatry approach underpins recently granted patents covering the use of ALTO-100 and ALTO-300 in biomarker defined populations –","length":153,"tagName":"p","attribs":{}},{"type":"text","content":"– Strong cash position of approximately $169 million expected to fund planned operations into 2028, and through at least four upcoming clinical study readouts –","length":160,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., March 20, 2025--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full-year ended December 31, 2024, and highlighted recent progress across its pipeline of clinical-stage product candidates.","length":408,"tagName":"p"},{"type":"text","content":""In 2024 we continued to advance ...